

Verquvo™ ,Vericiguat 2.5mg, 5mg and 10mg film-coated tablets. Approved name(s) of the active ingredient(s): Each film-coated tablet contains 2.5 mg, 5mg and 10mg Vericiguat micronized, respectively. Exipients: Cellulose microcrystalline,Croscarmellose sodium, Hypromellose, Lactose monohydrate, Magnesium stearate, Sodium laurilsulfate. **Indication:** 1. Vericiguat is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%. **Dosage and method of administration:** The recommended starting dose of VERQUVO is 2.5 mg once daily, taken with food. Double the dose of VERQUVO approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablets, VERQUVO may be crushed and mixed with water immediately before administration. VERQUVO is administered in conjunction with other heart failure therapies. If a dose is missed, it should be taken as soon as the patient remembers on the same day of the missed dose. Patients should not take two doses of VERQUVO on the same day. **Contraindications:** Verquvo is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators, such as riociguat. **Warnings & Precautions:** VERQUVO may cause symptomatic hypotension. Concomitant use of VERQUVO and phosphodiesterase-5 (PDE-5) inhibitors, such as sildenafil, has not been studied in patients with heart failure and is therefore not recommended due to the potential increased risk for symptomatic hypotension. **Undesirable effects:** Common: Anemia, Nausea, Dyspepsia, Vomiting, Gastroesophageal reflux disease Dizziness, Headache, Hypotension. For full listing of undesirable effects, please refer to the full product insert. **For further prescribing information**, please contact: Bayer Zydus Pharma Private Limited, Bayer House, Central Avenue, Hiranandani Estate, Thane, Maharashtra, India Pin-400607. Email: medicalinfo.india@bayerzyduspharma.com. **Source:** Version number: VE_2023_01 dated Mar 2023 Based on CCDS v03 dated 15 Feb 2023 and US indication statement approved dated 19-Jan-2021 Revision: Sep 2023 **For the use of healthcare professionals only.** (For use of consultant cardiologist and physician with a post graduate qualification in medicine only)